Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Lunn

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|December 21, 2023
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular testsMichael P Lunn
Journal of Neurology, Neurosurgery, and Psychiatry|May 24, 2025
Biomarker-based Alzheimer's diagnosis: learning to use p-tau217 wiselyMichael P Lunn
The Lancet. Neurology|March 20, 2021
Preventing expensive harms in Guillain-Barré syndromeMichael P Lunn
Current Opinion in Neurology|September 7, 2022
Guillain-Barré syndrome in an era of global infections and 21st century vaccinationMichael P Lunn
Current Opinion in Neurology|July 18, 2019
Neuropathies and paraproteinsMichael P Lunn
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2026
Poetry in practiceStephen Keddie, Michael P Lunn
Current Opinion in Neurology|June 11, 2024
Recent insights into haematology and peripheral nerve diseaseOliver Tomkins, Michael P Lunn
Current Opinion in Neurology|August 24, 2018
POEMS syndromeStephen Keddie, Michael P Lunn
BMJ Neurology Open|February 19, 2026
What is refractory CIDP?Aisling Carr, Michael P Lunn
Nature Reviews. Neurology|May 23, 2012
Neuromuscular disease: IVIg for neuromuscular disease-effective but expensiveRichard A Hughes, Michael P Lunn
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Journal of Neurology, Neurosurgery, and Psychiatry|December 21, 2023
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular testsMichael P Lunn
Journal of Neurology, Neurosurgery, and Psychiatry|May 24, 2025
Biomarker-based Alzheimer's diagnosis: learning to use p-tau217 wiselyMichael P Lunn
The Lancet. Neurology|March 20, 2021
Preventing expensive harms in Guillain-Barré syndromeMichael P Lunn
Current Opinion in Neurology|September 7, 2022
Guillain-Barré syndrome in an era of global infections and 21st century vaccinationMichael P Lunn
Current Opinion in Neurology|July 18, 2019
Neuropathies and paraproteinsMichael P Lunn
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2026
Poetry in practiceStephen Keddie, Michael P Lunn
Current Opinion in Neurology|June 11, 2024
Recent insights into haematology and peripheral nerve diseaseOliver Tomkins, Michael P Lunn
Current Opinion in Neurology|August 24, 2018
POEMS syndromeStephen Keddie, Michael P Lunn
BMJ Neurology Open|February 19, 2026
What is refractory CIDP?Aisling Carr, Michael P Lunn
Nature Reviews. Neurology|May 23, 2012
Neuromuscular disease: IVIg for neuromuscular disease-effective but expensiveRichard A Hughes, Michael P Lunn
Pageof 14